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by 
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The clearance of viruses is largely dependent upon the activation of T cells to generate a robust 
immune response. However, host responses are suppressed during chronic viral infections. In 
this thesis, we explored the role of Top2α in DNA topology in individuals with chronic HBV, 
HCV, and HIV infections. We found that Top2α protein expression and activity were low in T 
cells derived from chronically virus-infected individuals compared to healthy subjects. Using 
CD4+ T cells treated with Top2α inhibitor or poisoner as a model, we demonstrated that Top2α 
inhibition disrupts the DNA topology, suppresses DNA repair kinase (ATM), and telomere 
protein (TRF2) expression, and induces T cell dysfunction. These findings reveal that Top2α 
inhibition is a mechanism by which viruses evade the host responses and establish persistent 
infection, and thus, restoring Top2α levels could be a way of boosting immune responses during 
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 Chronic viral infections pose a major threat to public health. They cause debilitating 
illnesses associated with increased mortality and morbidity. During my master's thesis, I was 
interested in understanding the role of topoisomerase 2 alpha (Top2α) in T cell DNA topology, 
immune dysregulation, and DNA damage during viral infections. CD4+ T cells from chronic 
hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) 
infected individuals or treated with Top2a inhibitor or poisoner were the primary model used in 
this thesis. 
 Topoisomerases are enzymes that regulate the conformation of the DNA by creating 
transient breaks and resealing the DNA backbone almost at once. This means that a low level of 
expression or functional activity of this enzyme will cause some problems in DNA topology. On 
the other hand, the telomeres are hexameric nucleotide sequences (TTAGGG) that cap the ends 
of the eukaryotic chromosomes and are fundamental in maintaining genomic integrity. 
Shortening of the telomeres leads to DNA damage, poor cellular proliferation capability, and T 
cell dysfunction or apoptosis. 
 In the introduction, I begin by briefly talking about the virology, epidemiology, and 
transmission of HBV, HCV, and HIV infections. Then I proceed to discuss an overview of 
chronic viral infections and T cell dysregulation, chronic viral infections, and telomeric DNA 
damage. Finally, I conclude by elaborating on the role of topoisomerases and the possibility of 





Epidemiology, Virology, and Transmission of Chronic Viral Infections 
Hepatitis B Virus (HBV) Infection  
 The hepatitis epidemic was first recognized in 1883 during a vaccination program in 
Bremen Germany during which some shipyard workers who were injected with smallpox 
vaccine became icteric weeks after the vaccination.1 In the early 1940s, there was another major 
outbreak of hepatitis which occurred in American Army personnels following a possibly 
contaminated yellow fever vaccine. 1 However, the idea of its etiology remained mostly 
unknown until the mid-1960s when an antigen observed in the serum of thalassemia patients 
transfused with large amounts of blood was noted to be associated with post-transfusion 
hepatitis.1–4 This antigen (Australian Antigen) became a serological marker for active hepatitis B 
virus infection.1,2 This viral infection became a public health concern only after the laboratory 
markers of the hepatitis B viral infection (notably the antigen of the hepatitis B virus surface) 
was observed to have persisted in individuals with a chronic liver infection. 1 
 According to World Health Organization (WHO), by the end of 2015, it was estimated 
that approximately 257 million people were living with chronic hepatitis B virus infection and 
that this virus resulted in about 887,000 deaths, mainly from primary liver carcinoma. 5As in 
2016, just 10.5 percent of these populations were aware of their infection, and an estimated 4.5 
million of the individuals diagnosed were on antiviral therapy. Prevalence of hepatitis B was 
noted to be highest in the Western Pacific and African region where about 6.2 percent and 6.1 
percent of the adults were infected respectively; and lowest in the Eastern Mediterranean, 
Southeast Asian and European region with 3.3%, 2.0% and 1.6% of the population are affected. 5 
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Aaron M. Harris and his colleagues reported that about 2.2 million persons are infected with the 
hepatitis B virus in the United States, and 15 to 20% of these individuals are likely to die 
prematurely from hepatic complications and liver cancer. 6 
 HBV can be transmitted perinatally, through sexual contact with infected individuals, and 
parenteral transmission, which can be from intravenous drug use, transfusion of blood and blood 
products, dialysis, and exposure to infected body fluids such as seminal, vaginal fluids, and 
saliva. 
 HBV is a partially double-stranded DNA virus and belongs to the Hepadnaviridae viral 
family. It is an enveloped virus and has an icosahedral capsid.  The viral genome comprises four 
open reading frames (ORFs). The largest ORF known as the P gene, encodes the viral DNA 
polymerase. The S gene and domain, which is the second-largest ORF encodes the three 
enveloped proteins named large, middle, and small hepatitis B surface antigen (HbsAg). The C 
gene known as the core encodes the capsid protein, and finally, the X ORF which is the smallest 
encodes the 154 amino acid of the X protein known as the HBx protein. The HBx protein is 
associated with the ability of the virus to replicate and disrupt host cellular responses. Once the 
virus attaches to a host cell, it becomes uncoated. Inside the cell, the partially double-stranded 
genome is transported to the nucleus and converted to a covalently closed circular DNA. This 
covalent closed circular DNA serves as a template for the production of the viral transcripts. 7–10 
 Following infection with HBV, there is an initial phase of acute infection in which the 
affected individual may be asymptomatic or present with nausea, vomiting, increased liver span, 
and jaundice (yellowness of the eyes, skin, and urine). During this acute phase, the virus can be 
cleared within six months in 90-95% or may become chronic in about 5-10% in infected adults. 
This virus targets the liver cells, leading to chronic inflammation of the liver (viral hepatitis). 
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Hepatitis is a risk factor for liver cancer. Chronic HBV infected individuals express hepatitis B 
surface antigen (HBsAg) and hepatitis B e antigen (HbeAg) in their serum. HbsAg and HbeAg 
are used as serological markers for diagnosis. HBV infection is a vaccine-preventable disease 
with the vaccine having a notable safety profile since it became available in 1982. 5,7,11 
Hepatitis C Virus (HCV) Infection  
 In 1975, after the progress in the definite diagnosis of hepatitis A virus (HAV) and HBV 
and identification of other hepatitis inducing agents, Feinstone and his colleagues noticed that 
most of the post-transfusion associated hepatitis in twenty-two patients were negative for HBV 
and HAV. 12 In another report, a similar finding was observed in thirty-four cardiac surgery 
patients who developed hepatitis after blood transfusion postoperatively.13 This occurrence 
prompted the need for the identification of this non-A non-B hepatitis (NANBH) agent. It was 
not until 1989 more than a decade later that Choo and his colleagues isolated a complementary 
DNA (cDNA) clone derived from the RNA molecule present in the serum of a patient infected 
with NANBH agent. This NANBH agent was called HCV by this group.14 
 According to the WHO, an estimated 170 million people are infected with chronic HCV 
infections worldwide; and about 1.2 million individuals died from HCV infections in 2015. 
These deaths were primarily due to its associated liver complications, notably liver cirrhosis and 
HCC. 15,16 In America, an estimated 3.5 million people are infected with chronic HCV 
infection.16 The prevalence of HCV has skyrocketed in recent years due to the high rate of 
intravenous drug abuse.    
 HCV can be transmitted mostly through contact with infected blood and blood products, 
which may be through intravenous drug use, blood transfusion, unsafe sexual practices, organ 
transplantation, and perinatally from mother to child during delivery.  
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 HCV is an enveloped, single-stranded linear RNA virus. It has an icosahedral 
nucleocapsid of about 9.6 kb and belongs to the Flaviviridae family. It consists of a single ORF 
that encodes a single viral polyprotein. This polyprotein is cleaved afterward by viral and host 
proteases into ten different viral proteins with distinct features namely envelope glycoproteins E1 
and E2, core protein, p7 ion channel protein, and finally the NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B proteins, all of which are non-structural proteins. These proteins promote viral 
replication, entry, and viral pathogenesis.17,18  
 Once infected with HCV, there is an initial phase of acute infection in which the 
individual is asymptomatic or may have non-specific clinical signs, such as malaise, anorexia, 
and abdominal discomfort. Infection tends to resolve in 15 to 20 percent of affected individuals. 
However, 75 to 80 percent of individuals develop chronic HCV infection.17 There is currently no 
vaccine for HCV infection, and attempts aimed at minimizing the burden of HCV infection are 
geared towards primary and secondary prevention strategies as well as antiviral treatment. 
 Human Immunodeficiency Virus (HIV) Infection 
 It was thought that simian immunodeficiency virus (SIV),  a virus that infects nonhuman 
primates such as chimpanzees and sooty mangabey monkeys in sub-Saharan Africa, mutated into 
HIV in humans after crossing several cross-species barriers; and that hunters in the southeastern 
part of Cameroon had contact with the blood of these infected animals.19 Retrospective analysis 
of the blood samples taken from a man living in Kinshasa in 1959 detected HIV, and this was the 
first verified case of HIV infection. Kinshasa was a growing place at that time with a thriving sex 




 According to the WHO, an estimated 37.9 million people are living with HIV as of 2018, 
with about 1.7 million new infections and 77,700 HIV-related deaths in 2018. In 2018, 23.3 
million (62%) of the affected individuals were receiving antiretroviral drugs. HIV can be 
transmitted through unsafe sexual practices, intravenous drug use, blood and blood products, and 
perinatally from mother to child.21,22 
 HIV is a single-stranded enveloped positive-sense virus with a complex, conical capsid 
belonging to the retroviridae family of RNA virus, a subgroup of the Lentivirus. It has a diploid 
genome. It encodes three structural genes, namely envelope (that codes for glycoproteins gp120 
and gp41), gag gene (that codes p24 and p17, which are capsid and matrix proteins, 
respectively), and the pol gene (that codes for reverse transcriptase, protease, and integrase). HIV 
mainly targets T cells and macrophages. The enveloped proteins mediate entry and attachment of 
the virus to the T cells, and once entered the cytoplasm of the host cell, and the capsid releases 
the viral RNA. This viral RNA is reverse transcribed into double-stranded DNA (dsDNA) and 
incorporated into the host genome by an enzyme called integrase. On cellular activation, the viral 
DNA is continuously transcribed, and new transcripts are produced.20,23,24 
 Before the commencement of antiretroviral therapy (ART), HIV infection progresses 
through three main phases. There is an initial phase of acute infection characterized by non-
specific symptoms such as fever, chills, and headache, and lasts for two to four weeks. This 
phase is marked by rapid viral replication, dissemination, and seeding into lymphoid tissues. This 
is followed by clinical latency (chronic HIV infection) whereby viral replication occurs at a very 
low level. At this point, the infected individuals may be asymptomatic. This phase progresses to 
AIDS eight to ten years and marked by systemic immunodeficiency, opportunistic infections, 
AIDS-defining illness, and eventually death without ART. Even though there is not yet a cure for 
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HIV infection, adequate adherence to ART therapy helps suppress the viral load, and these 
individuals tend to live longer and healthier lives.   
Chronic Viral Infections and T cell Dysregulation 
 The clearance of these viruses, as well as other pathogenic infections, is mostly 
dependent upon the activation of T cells by the adaptive immune system. However, by some 
incompletely understood mechanisms, these T cell responses and adaptive immune responses 
become depressed and inefficient to clear viral infections. Thus, viral infection-mediated 
symptoms persist for a long time. Despite this, exposure to these infections contributes to the 
shaping and development of our immune systems.   
 Laboratory mice which are known to live in sterile confinements were observed to have 
less developed immune system evidenced by the lack of CD8+ T cells, a vital arm of the adaptive 
immune system compared to commercial pet store mice. Furthermore, significant changes to 
many immune cell lineages were observed on co-housing with commercial pet store mice. Also, 
Reese and his group reported that vaccine and immune responses were altered in laboratory mice 
on the persistent exposure to common pathogens compared to their mock mice, confirming 
possible profound immune boosting with exposure to pathogens.25 This means that the 
interaction between the pathogens and host cells determines to a large extent, the balance 
between disease progression and host immunity.  
 Chronic viral infections have been shown to cause T cell exhaustion, which is a state of 
low proliferative potential as a result of continuous antigenic exposure. Proper differentiation of 
T cells, especially the CD4+ T cells to Th1 subtype, is essential in the control of chronic viral 
infections. Using in vivo labeling techniques, Beura and his group studied the impact of viral 
persistence on T cell differentiation on mice models. They  compared immune responses to 
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different strains of lymphocytic choriomeningitis virus (LCMV) known to cause acute and 
chronic infections; and observed that after the first week of infection, there was a marked  
reduction in the cytokine-producing cells in the mice infected with the LCMV strain of chronic 
infection compared to the acute infection mice models.26 This means that a fully functional CD4+  
T cell repertoire plays a crucial role in halting viral persistence.  
 Similarly, studies in humans noted loss in the proliferative ability and functionality of the 
CD4+ T cells, especially in HIV and HCV infections that lead to chronic viral persistence. This 
loss in responsiveness has been thought to be a result of poor differentiation of the CD4+ T cells 
into functional subsets and deficiency in the production of cytokines and co-regulatory 
molecules. 27–30 
Telomeric DNA Damage and Chronic Viral Infections 
 Chronic viral infections are characterized by the upregulation of biomarkers of 
senescence, such as phosphorylated histone H2AX (γ-H2AX), miR-21 and p16INK4A, and most 
importantly telomere shortening.31–33 
 Telomeres are repetitive hexameric nucleotide repeat sequences (TTAGGG) found at the 
ends of the eukaryotic chromosomes, along with a complex of proteins called shelterin. They are 
paramount for maintaining genomic integrity and prevent loss and fusion of the chromosomal 
ends. The shelterin proteins, which includes telomeric repeat-binding protein 1 (TRF1), 
telomeric repeat-binding protein 2 (TRF2), protection of telomere 1 (POT1), TRF1 and TRF2 
interacting nuclear protein 2 (TIN2), TIN2 and POT1 interacting protein 1 (TPP1), TIN2 and 
POT1 interacting protein 1 (TPP1), and repressor activator protein 1 (RAP1) function together to 
protect the telomeres. The telomeres shorten during each cell division and the telomerase enzyme 
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function to replenish the telomere length. Cells with shortened telomeres are recognized as DNA 
damaged with phenotypic reconditioning that drives cellular apoptosis.   
 Kim and his group knocked out specific subunits of the shelterin complex in the human 
cell line using the CRISPR/Cas 9 technology to systematically profile the role of each shelterin 
protein in maintaining telomere integrity and function.  They noted that removal of any subunit 
of the shelterin complex leads to telomere deprotection, chromosomal fusion, induction of the 
DNA damage response proteins, such as ataxia -telangiectasia mutated (ATM), and metabolic 
dysfunction, suggesting a tightly regulated process in telomere assembly.34 
 Nguyen et al. reported that suppression of TRF2 protein expedited telomere attrition, 
apoptosis, and  DNA damage in individuals with chronic HCV infection compared to healthy 
subjects. 35 Also, there are  reports of telomere shortening impairing DNA damage repair and 
undoubtedly having  pathological repercussions.36–39 
Topoisomerases and Topoisomerase Inhibitors or Poisoners as Therapeutic Options 
 There is a strong relationship between the DNA structure and the cellular processes that 
occur in the cells. The DNA is a double-stranded helical structure wound around a core of 
histone proteins and condensed in a chromatin assembly. While this conformation is essential in 
maintaining and preserving genetic information, it also poses some form of topological 
problems. This is because nearly all the cellular processes such as DNA replication, transcription 
as well as gene recombination involve separation of this double helix in order to access the 
preserved information in the DNA and could create torsional stress on the DNA structure. This 
topology could be in the form of supercoils, catenations, and molecular knots and must be 
resolved for effective physiological functions and efficient gene expression. These constraints 
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are resolved by DNA topoisomerases, which are enzymes that adjust the DNA topology in the 
cell. 40 
 These topoisomerases make transient single- or double-stranded breaks in the DNA 
backbone; therefore, allowing the release of this topological stress. At the end of the genetic 
process, the backbone is ligated immediately. These enzymes are indispensable for the survival 
of all entities and, thus, common to all cellular structures. There are two main categories of 
topoisomerases, type I, and type II. While type I topoisomerases resolve DNA entanglements by 
making a single break in one of the DNA strands, passing the uncleaved DNA strand through the 
break and finally resealing the backbone, type II topoisomerases make double-stranded breaks 
through which adjustments in the DNA topology occurs. 41 
 Top 2α, a type II topoisomerase, is fundamental for the vitality of rapidly growing cells. 
Its level rises significantly during G1 to S and G2 to M cell cycle progression. Despite being 
crucial for cell growth and vitality, it tends to fragment the genome. This is as a result of the 
generation of a phosphotyrosyl bond that covalently links the protein to the 3’ – hydroxyl and 5' – 
terminus of the DNA moiety called Topoisomerase II –DNA cleavage complexes (Top2cc). 
Interestingly, this Top2cc is transitory, easily reversible, and is paramount for it to perform its 
genetic function; and thus, their levels must be maintained tightly.  Low levels of the Top2cc 
lead to the poor separation of daughter chromosomes during mitosis, and thus, these cells die 
from a fatal mitotic breakdown. Also, increased levels of Top2cc lead to the conversion of these 
transient double-stranded breaks into permanent double-stranded breaks that can overpower the 
cells and initiate cell apoptosis. 42–44 
 Since Top2α is highly expressed in rapidly proliferating cells such as cancer cells, it has 
been used as a prognostic cancer cell biomarker and a primary target of many anticancer drugs as 
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well as some antibacterial medications such as fluoroquinolones. These inhibitors act by two 
recognizable mechanisms: either by inhibiting the catalytic activity of Top2α from completing 
the ligation of the cleaved DNA molecules or, by increasing the levels of the Top2cc. 41,45–
54While much is known about the role of topoisomerases in cancer and bacterial cells; very little 
is known on how Top2α level is regulated during chronic viral infections. 
Hypothesis 
 Topoisomerase 2 alpha levels may be disrupted, leading to DNA damage and immune 





















The study protocol was approved by the Institutional review board of East Tennessee State 
University and James H. Quillen VA Medical Center, Johnson City. All participating adults in 
this project signed the informed consent form.  
Subjects 
The study groups consisted of four populations: Chronically HBV-infected individuals on 
therapy, chronically HCV infected patients, and chronically HIV-infected patients on 
antiretroviral therapy; and age-matched healthy subjects. Blood samples from healthy subjects 
were supplied by Physicians Plasma Alliance in Gray, Tennessee, and negative for HIV, HCV, 
and HBV infection.  
Cell Isolation and Culture 
Peripheral Blood Mononuclear Cell (PBMC) Isolation 
 In studying human immune response to diverse stimuli, PBMCs are isolated from whole 
blood.  These cells are composed of a diverse population of cells of varying frequencies; they 
include monocytes, lymphocytes, dendritic cells, and stem cells. 
 PBMCs were isolated from the whole blood of the study participants by Ficoll density 
centrifugation using the Ficoll-Paque plus solution (GE Healthway, Piscataway, NJ; C# GE17-
1440-03) and the manufacturer’s instructions were followed. In brief, anticoagulant-treated blood 
diluted with an equal volume of 1x RPMI 1640 with L-glutamine (Corning Mediatech C# 10-
040-CV) was layered over 15ml of Ficoll-Paque plus solution in a 50 ml centrifugation tube. 
Care was taken to prevent the mixing of the solution and the diluted blood sample. The blood 
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sample was centrifugated at 2000 rpm for 20 minutes at 24 degrees with acceleration and 
deceleration speeds set at 1. After centrifugation, visible layers were noted and using a sterile 
pipet, the upper layer containing the plasma was aspirated and was discarded or stored for future 
use. At the interphase between the plasma and the Ficoll solution lies the PBMCs. They were 
carefully removed and transferred into another 50 ml conical tube containing three times the 
volume of RPMI 1640 media and centrifuged at 1800 rpm at room temperature for 8 minutes 
with acceleration and deceleration speeds set at 9 to remove any remaining Ficoll solution. The 
cells were counted, and the percentage of live cells estimated by trypan blue staining (1:1 
dilution) using the automated cell counter (Invitrogen Countess II FL automated cell counter C# 
AMQAF1000) 
Cryopreservation 
 Freshly isolated PBMCs are either used immediately or stored for future use in liquid 
nitrogen. For long term storage, isolated PBMCs were suspended in freezing medium that is 50% 
RPMI 1640 medium by volume containing 10% dimethyl sulfoxide (DMSO) by volume (Sigma 
Life Science C# D2660-100ml) and 40% fetal bovine serum (FBS) by volume (Invitrogen 
Corporation C# 26140-079) and stored at –80 degrees in cryotubes. The next day, they are 
transferred to the liquid nitrogen tank and stored for future use.  
CD4+ T Cell Isolation  
  CD4+ T cells were isolated from the PBMCs using the human CD4+ T cell negative 
selection isolation kit (C# 130-096-533) and LS columns from Miltenyl Biotec Inc., Auburn, CA 
and the manufacturer's cell isolation protocol was followed. Briefly, frozen PBMCs were thawed 
in a water bath at 37-degree Celsius and transferred to a tube containing the thawing medium of 
RPMI 1640 to wash the cells. The samples were centrifuged at 900 rpm for 5 minutes. The 
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supernatant was discarded, and the cells were suspended in 10Ul of biotin- antibody cocktail and 
40ul of isolation buffer per 107 cells. The suspension was mixed well by slow pipetting and 
incubated for 5 minutes at 4-degree Celsius. The biotin-antibody cocktail is made up of anti-
human biotin-conjugated monoclonal antibodies against CD8a, CD14, CD15, CD19, CD36, 
CD56, CD123, CD123, TcRγ/δ and CD235a. 
Next, 30ul of isolation buffer and 20 ul of CD4+ T cell microbead cocktail was added per 107 
cells to the suspension, mixed well, and incubated in 4-degree Celsius for 10 minutes and 
subsequent magnetic cell separation. The flow-through contained the purified CD4 T cells. The 
cells were counted by trypan blue staining in a counting chamber and utilized for further assays. 
Cell Culture 
 Isolated CD4 T cells were suspended in complete media of RPMI 1640 media containing 
10% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA), 100IU/ml of 
Penicillin and 2mM L-glutamine (Thermo Scientific, Logan, Utah); and seeded into appropriate 
well plates. Topoisomerase II alpha (Top2α) is only expressed in activated T cells. As such, the 
cells were stimulated with purified NA/LE mouse anti-human CD3 antibody clone HIT3 α (BD 
Pharmamingen brand C# 555336) and purified NA/LE mouse anti-human CD 28 antibody clone 
CD28.2 (BD   Pharmingen brand, C#555725) and cultured at 37-degree Celsius and 5% CO2 
atmosphere for 3 days and subsequently used for downstream applications.  
RNA Isolation and cDNA Synthesis 
 Total RNA was isolated from 1x 106 CD4 T cells using the RNeasy Mini Kit (Qiagen C# 
7410), and the manufacturer's instructions followed accordingly. Cultured cells were harvested 
and washed with phosphate-buffered saline (Lonza BioWhittaker DPBS, C#17-512F) by 
centrifuging at 1500rpm for 5 minutes, and the supernatant removed. The pelleted cells were 
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disrupted and homogenized by the addition of 350uL of Buffer RLT (supplied) per 5 million 
cells and vortexing for 1 minute. The lysate was centrifugated for 3 minutes at 10000 rpm, and 
the supernatant was removed by pipetting. One volume of cold 70 percent ethanol was added to 
the lysate. It was mixed thoroughly by pipetting, and 700uL of the sample was transferred 
immediately into an RNeasy Mini spin column placed in a 2ml collection tube (supplied). The 
sample was centrifuged for 15 seconds at 10000rpm, and the flow-through was discarded. 700uL 
of Buffer RW1 (supplied) was added to the into the spin column followed by brief centrifugation 
at 10000rpm for 15 seconds and the flow-through discarded. 500ul of Buffer RPE (supplied) was 
added to the spin column and sample centrifuged at 10000 rpm for 15 seconds with the flow-
through discarded. Finally, the spin column was placed in a new 1.5ml collection tube (supplied), 
and 50ul of RNase free water supplied) was added to the spin column membrane and 
centrifugated at 10000rpm for 1 minute to elute the RNA. RNA concentrations and quality were 
determined by photometric analysis (Eppendorf BioPhotometer Model number 6131).  
2 ug of RNA per 20uL reaction was reverse transcribed to cDNA using the High Capacity cDNA 
Reverse transcription Kit (Applied Biosystems C# 4368814) and the manufacturer's instructions 
followed accordingly. The components of the kit were thawed on ice, and the reverse 
transcription (RT) master mix was prepared on ice, followed by the manufacturer's 
recommended volumes for each of the reagents, as shown in Table 1 below. 10uL of RNA 
sample was added to 10uL of the RT master mix and mixed thoroughly by pipetting. The sample 






Table 1: Reverse Transcription Master Mix Components 
Component Volume per reaction (uL) 
10X RT Buffer 2.0 
25X dNTP Mix (100mM) 0.8 




RNase Inhibitor 1.0 
Nuclease free water 3.2 
Total per reaction 10 
 
The tubes were placed on the thermal cycler (Biorad T100 Thermal Cycler C#1861096) and 
programmed using the thermal cycler conditions recommended by the manufacturer and listed in 
Table 2. 
Table 2: cDNA Reverse Transcription Thermal Cycler Conditions 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time (minutes) 10  120  5  ꝏ 
 
Quantitative Real-time Reverse Transcriptase PCR Analysis (RT-PCR) 
 The cDNA synthesized from the reverse transcription reaction was incubated with a 10uL 
SYBR Green master mix (Biorad, USA iTaq Universal SYBR Green one-step kit C#1725150), 
8uL of distilled filtered water, 1 uL of forward and reverse primer per 20uL reaction. The 
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primers used were purchased from Thermo Fisher, and primer concentrations were optimized to 
a final concentration of 5uM/uL. GAPDH was used as the loading control, and gene expression 
was determined using the 2-∆∆ct method. The list of primer sequences used are shown in table 3 
below 
Table 3: List of PCR primers used in this study. 
Primers Forward sequence Reverse sequence 
Top 2α 5′-ACCATTGCAGCCTGTAAATGA-3’ 5′-GGGCGGAGCAAAATATGTTCC-3’ 
hTERT 5′-CCAAGTTCCTGCACTGGCTGA-3′ 5′-TTCCCGATGCTGCCTGACC-3′ 
GAPDH 5′-TGCACCACCAACTGCTTAGC-3′ 5′-GGCATGGACTGTGGTCATGAG-3′ 
 
Protein Extraction and Western Blotting 
 CD4+ T cells were harvested and washed with 500uL of iced cold isolation buffer by 
centrifuging at 1500rpm for 5 minutes. The supernatant was decanted, and the cells were 
suspended in RIPA buffer (Boston BioProducts, C# BP-407) with a 1x pierce protease inhibitor 
tablet (Thermo Scientific, C# A32953). The samples were mixed thoroughly by vortexing for 
15s, and the contents were incubated for 30 minutes at 2-degree Celsius on a rocking platform. 
The lysates were centrifugated for 15 minutes at 13200rpm, and the supernatant containing the 
purified protein was transferred into a 1.5mL tube and kept on ice. Protein concentration was 
determined by the Bradford protein concentration assay, and a 4x SDS loading buffer was added 
to the lysates. The lysates were heated for 5 minutes at 95-degree Celsius to denature the 
proteins. Following SDS-PAGE gel electrophoresis, the proteins were transferred onto a PVDF 
membrane in an overnight wet transfer. The membranes were blocked with 5% skim milk in 1x 
tris-buffered saline containing 0.1% tween (TBST) for 1 hour at room temperature on a rocking 
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platform; thereafter, they were washed with 1x TBST thrice and probed with specific primary 
antibodies (in 1x BSA solution) and secondary antibodies (in 5% skim milk). Primary antibodies 
included Top2α, PARP1, Caspase 3, gamma γH2AX, TRF2, TRF1, TIN2, RAP1, POT1, β-actin, 
ATM, and CHK2; secondary antibodies included horseradish peroxide conjugated anti-
mouse/anti-rabbit IgG antibodies (Cell Signalling). Chemiluminescence signal was detected by 
the Biorad Chemi DocTM MP Imaging system, and western blot images were analyzed with the 
image lab software (Biorad). 
Flow Cytometry (FCM) 
 Cytokine production, gamma H2AX levels (a DNA damage marker), Annexin V/7-
Amino Actinomycin D(7-AAD) assay for cell apoptosis determination and telomere length 
estimation were analyzed by flow cytometry.  
Intracellular Cytokine Staining 
 Cytokine production and secretion is a key determinant of the strength of cellular 
immune response. Cytokines are involved in numerous immune responses, including but not 
limited to activation of T cell proliferation by interleukin-2 (IL-2) and induction of anti-viral 
proteins by interferon-gamma (INF-gamma); thus, intracellular staining of INF-gamma and IL-2 
was analyzed to determine antigen-specific response.   
 Briefly, 5 million CD4+ T cells were stimulated with CD3/CD28 antibodies, treated with 
DMSO (control) or etoposide (a Top2a inhibitor), and cultured in a 48 well plate for three days. 
Brefeldin A (a protein transport inhibitor) and ionomycin were added to the samples 6 hours 
before harvesting the cells. The cells were washed with isolation buffer by centrifugation for 5 
minutes at 1500 rpm, and the supernatant was discarded. The pellets were suspended in 100uL of 
fixation buffer (Biolegend, C#420801) and incubated in the dark for 40 minutes. The lysates 
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were centrifugated at 1500 rpm for 5 minutes and the supernatant discarded. The fixed cells are 
suspended in a 1x permeabilization buffer and centrifugated at 1500 rpm for 5 minutes, and the 
supernatant removed. The cells pellets were resuspended in 50uL of 1x permeabilization buffer, 
and 1uL of fluorescence -conjugated antibody of interest was added to the fixed cells for 45 
minutes. The fixed and intracellularly labeled cells were resuspended in 50uL of cell staining 
buffer alongside appropriate controls (unstained, IL-2 only and INF- gamma only) and analyzed 
by FCM 
Annexin V/ 7-AAD Staining Assay 
 Apoptosis of cells was determined by staining with Annexin V and 7-AAD solutions. 
This assay is based on the principle that cells undergoing apoptosis flip their membrane by the 
action of scramblases and phosphatidylserine, a normally intracytoplasmic phosphoprotein is 
exposed to the outer plasma membrane and this can be bound tightly by annexin V. Also, these 
apoptotic cells have permeable membranes allowing the leakage of DNA contents and 7-AAD, a 
DNA binding dye can adhere to the double-stranded DNA and exclude dead cells.  
Briefly, 1 million CD4 T cells were stimulated with CD3/CD28 antibodies, treated with DMSO 
(control) or etoposide (a Top2α inhibitor), and cultured in a 48 well plate for three days. The 
cells were harvested and washed once with ice-cold PBS and once by 1x binding buffer by 
centrifugation at 1500rpm for 5 minutes, and the supernatant was removed. The cell pellets were 
resuspended in 1x binding buffer at 1 million cells/mL, and 100uL of the cell suspension was 
transferred to a 1.5mL tube. 5uL of fluorescently labeled Annexin V (BioLegend, C# 640922) 
was added to the samples and incubated for 10 minutes in a dark room and subsequently 
centrifugated at 1500 rpm for five minutes. The supernatant was removed, and cells resuspended 
in 100uL 1x binding buffer and incubated with 5uL of 7-AAD staining solution (BioLegend, C# 
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640922) for 15 minutes away from light. 400uL of 1x binding buffer was added, and the sample 
analyzed by FCM. 
Fluorescent In- Situ Hybridization (Flow-FISH) 
 The flow-fish technique uses fluorescently labeled nucleic acid probes that bind repetitive 
sequences at specific sites of the chromosome; and as such, has been used to measure telomere 
length. Briefly, PBMCs were isolated, stained with Alexa Flour 647 anti-human CD4 antibody 
(CD4-A647) per 1 million cells in a 100uL staining buffer and fixed with cell fixation buffer 
(BioLegend, C#420801) for 30 minutes at room temperature. After fixation, cell samples were 
centrifugated and supernatant decanted. The cells were resuspended in 100uL of hybridization 
buffer and incubated with 1uL of telomere PNA probe (PNA Bio, C#F1009) at a concentration 
of 0.3ug probe/mL for 15 minutes at room temperature. The samples were placed in the 82-
degree fridge for 10 minutes and then overnight at room temperature. The next day, the cells 
were washed with post hybridization buffer twice and centrifuged at 2400rpm for 7 minutes, and 
the supernatant removed. The cells were resuspended in isolation buffer and analyzed by FCM 
γ-H2AX Staining for Apoptosis 
 DMSO (control) or Top2a inhibitor-treated cultured cells were harvested and washed was 
with isolation buffer, centrifugated, and the supernatant removed. The cells were fixed in a 1:1 
dilution ratio and incubated for 15 minutes in a dark cupboard at room temperature. 
Subsequently, the cells were washed with 800ul of isolation buffer, and the supernatant removed.  
The cells were resuspended in a FoxP3 fixation/permeabilization staining buffer (eBioscienceTM, 
C# 00-5523-00) in a ratio of 1:3 (concentrate/diluent) and incubated for 45 minutes in a dark 
cupboard. The cells were washed isolation buffer and resuspended in 50uL of 1x 
permeabilization buffer made by diluting a 10x permeabilization buffer (eBioscienceTM, C# 00-
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5523-00). 1uL of fluorescently labeled H2A.X antibody (BioLegend, C# 613404) was added to 
the cells and incubated for 40 minutes at room temperature away from light. The samples were 
washed with isolation buffer and resuspended in isolation buffer for analysis by FCM. 
Confocal Microscopy 
 Following DNA damage, there is a recruitment of p53-binding protein 1(53BP1) to the 
damaged site. 53BP1 serves as a docking platform for the recruitment of the DNA damage repair 
proteins. In telomeric DNA damage, the interaction between 53BP1 and TRF1(one of the 
proteins in the shelterin complex) forms a DNA damage focus called telomeric dysfunction-
induced foci (TIF). TIFs recognized by the co-localization of TRF1 and 53BP1 serve as a marker 
of telomeric DNA and are easily detected by confocal microscopy combined with 
immunofluorescent staining. 
  CD4+ T cells were stimulated with CD3/CD28 antibodies and cultured for three days. 
The cells were harvested and washed briefly with isolation buffer. Cells were fixed with 2% 
paraformaldehyde for 20 minutes, followed by permeabilization with 0.3% Triton X 100 in 1X 
phosphate-buffered saline solution (PBS) for 10 minutes. After blocking the samples with 5% 
fetal bovine serum for 1 hour, they were incubated with rabbit anti-53BP1(Cell Signalling) and 
mouse anti-TRF1(Thermo Fisher) primary antibodies overnight at 4 degrees. 
 After incubation, the samples were washed with 1X PBS three times and stained with 
fluorescence-labeled secondary antibodies anti-rabbit IgG-Alexa Flour 488 and anti-mouse IgG-
Alexa Flour 555(Invitrogen) in the dark for 1 hour. The cells were washed with 1X PBS, and for 
nuclear staining, the samples were treated with DAP1 Flouromount-G (SouthernBiotech, 
Birmingham, AL) Fluorescence images were acquired using a confocal laser-scanning inverted 
microscope (Leica Confocal, Model TCS sp8, Germany) 
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Topoisomerase IIα Activity Assay 
 Top2α activity was quantified by Topoisomerase II Assay Kit -plasmid-based (TopoGen, 
Inc. Florida USA, C#TG1001-1), and the manufacturer's instructions were followed. In brief, 
Cell extracts isolated from purified CD4+ T cells were incubated with plasmid DNA substrate 
and 5X complete reaction buffer (supplied) for 30 minutes at 37 degrees. 4uL of 5x stop buffer 
was added to the mixture, and samples were loaded onto 1% ethidium containing -agarose gel 
with marker DNA loading dye and run at 120V for 30 minutes. Gels were destained in water for 
15 minutes before imaging with a UV transilluminator (Biorad Chemi DocTM MP Imaging 
system). The intensity of the supercoiled DNA was analyzed by gel densitometry. 
Statistical Analysis 
 GraphPad Prism 7 software was used to analyze the data and are presented as mean ± 
SEM or median with interquartile range. Unpaired Student's t-test or paired T-test was used to 
compare the differences between two groups. Multiple groups were analyzed by one-way 
ANOVA with Tukey's HSD multiple comparison test or non-parametric Mann-Whitney U test. P 












 The workflow of the study is shown in Figure 1. Firstly, PBMCs were isolated from the 
whole blood of chronically HIV-, HCV-, HBV- infected subjects and healthy subjects by Ficoll 
density centrifugation. From the PBMCs, CD4+ T cells were purified by negative selection using 
the T cell isolation kit. The cells were stimulated with anti-human CD3/CD4 antibodies and 
cultured in an RPMI-containing medium. The mRNA level of Top2α and other genes of interest 
was determined by RT-PCR. Next, the protein expression of Top2α, the shelterin proteins, and 
the DNA damage associated proteins were determined by Western blotting. Subsequently, the 
effect of Top2α inhibition on T cell function and cellular apoptosis was evaluated by flow 
cytometry. The telomere length was detected by flow-FISH. And finally, immunofluorescence 
staining combined with confocal microscopy was used to ascertain if Top2α mediated DNA 




 Figure 1: The flow of experimental procedures 









Top2α Protein Level is Inhibited during Chronic Viral Infections 
 The mechanism by which chronic viral (HBV, HCV, HIV) infections alter T cell 
responses and cause cellular senescence remains poorly understood. Since Top2α is essential in 
resolving topological problems in the DNA, we hypothesized that its level might be altered 
during chronic viral infections.   
 Top2α is only expressed in activated T cells. We examined Top2α protein levels in anti-
CD3/CD28-activated CD4+ T cells obtained from chronically HIV-, HCV-, and HBV-infected 
individuals and compared to healthy subjects by Western blot. As shown in Fig. 2, Top2α level 
was significantly lowered in CD4+ T cells obtained from the chronically virus-infected patients 
compared to healthy subjects. The next step was to determine the point at which the inhibition 
occurred. Top2α mRNA levels were measured in CD4+ T cells from the same subjects by real-
time qPCR.  As shown in Fig. 3, there was no statistical difference observed at the gene level 
between the healthy and the virus-infected individuals. These data suggest that Top2α expression 





Figure 2: Top2α protein expression between healthy and chronically HBV-, HCV-, and 
HIV-infected individuals. Summary data and representative blot image are shown. β-actin was 
used as the loading control. Data were analyzed by using unpaired T-test and reported as 
mean±SEM, and n represents the number of subjects tested.  
 
Figure 3: Top2α gene expression between healthy and chronically HBV-, HCV-, and HIV-
infected individuals determined by real-time RT-PCR. GAPDH was used as the loading 
control. Data were analyzed by using unpaired T-test and reported as mean ± SEM, and n 
represents the number of subjects tested. 
 
Top2α Activity is Suppressed during Chronic Viral Infections 
 Top2α is a type IIA topoisomerase nuclear enzyme that relieves topological stress in 
DNA in an ATP dependent process. It does this by creating double-stranded breaks in the 
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phosphate backbone of the DNA and reseals this almost immediately. By so doing, it relaxes the 
DNA, allowing effective gene function. Top2α activity level correlates with how well it can 
relax supercoiled DNA and decatenate kinetoplast DNA (kDNA). Thus, we employed a plasmid-
based kDNA Top2α assay kit (Topogen Inc.) to evaluate Top2α activity between healthy and 
virus-infected individuals.  
 Catenated kDNA is a large cluster of interwoven DNAs that does not enter the 1 % 
agarose gel due to its size. Incubation with Top2α effectively decatenates the kDNA into 2.5kb 
monomeric minicircles (open or closed circular rings) that migrate swiftly into the gel. Top2α 
activity was compared between HS and individuals with chronic viral infections. As shown in 
Fig. 4, the linearized kDNA (lane 1) and decatenated kDNA (lane 2) were used as positive 
controls, extracts from non-stimulated healthy subjects was used as negative control (lane 3), 
kDNA treated with nuclear extracts from stimulated healthy (lane4), HBV (lane 5), HCV (lane 
6), HIV (lane7) subjects  resulted in differing degree of decatenation products in the gel. 
Since Top2α is only expressed in TCR-stimulated cells, it is not surprising that no decatenated 
DNA topisomers were observed in the gel as Top2α was not expressed. The topological stress 
was not resolved, and thus, the large catenated kDNA failed to enter the agarose gel. 
Interestingly, DNA extracts from stimulated HBV-, HCV-, and HIV-infected subjects were 
unable to decatenate the kDNA effectively when compared to HS. From this experiment, we can 




Figure 4: Top2α activity between healthy and chronically HBV-, HCV-, and HIV-infected 
individuals. Summary data and representative imaging of Top2α cleavage assay. The bar chart 
represents the relative levels of closed circular monomeric topoisomers from four independent 
samples, and n represents the number of subjects tested.  
 
Top2α Inhibition Induces T Cell Dysfunction 
Top2α is a well-characterized biological target owing to its indispensable role in modifying 
topological constraints during cell survival and replication. As such, its inhibitor has played an 
essential role as cancer therapeutics and antibacterial agents. In exploring the role of Top2α 
inhibition on T cell function, Top2α inhibitor-treated cells were used as models. Etoposide (ETP) 
and ICRF -193 are topoisomerase II inhibitors or poisoners, and they exert their actions by 
inhibiting the catalytic activity of Top2α, and in so doing, could convert the transient double-
stranded breaks into permanent breaks, thereby damaging the genome.  TCR-stimulated CD4+ T 
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cells derived from healthy subjects were treated with DMSO (control cells) or ETP or ICRF193 
(Top2α inhibitor-treated cells) at different time points (6h, 24h, 48h, and 72h) and Top2α 
expression was observed. As shown in fig. 5a and 5b below, Top2α expression was noticed by 
48h post culture, and stronger levels were seen by 72h after TCR stimulation in ICRF193 treated 
cells. 
 
Figure 5. Time-dependent expression of Top2α in TCR-stimulated, inhibitor-treated cells 
a) Representative Western blot image of Top2α expression in CD4+ T cells treated with  2ug/ml 
of ICRF193 at 6h, 24h, 48h, and 72h after TCR stimulation. GAPDH served as the loading 
control. b) Representative Western blot image of Top2α expression in CD4+ T cells treated with 
0.2 uM of ETP at 6h, 24h, and 48h after TCR stimulation. β-actin was used as the loading 
control. 
 
To determine the impact of Top2α inhibition on T cell function, cytokine production was 
accessed in TCR-stimulated cells exposed to varying concentrations of ETP ranging from 0 uM 
to 1.0 uM after cell culture for three days by flow cytometry. Cytokine production and secretion 
are the hallmarks of a functioning T lymphocyte. Production of interleukin -2 (IL-2) and 
interferon-gamma (INF-γ ) was compared in ETP-treated cells versus DMSO control cells. As 
shown in Fig. 6a, the percentage of IL-2 and INF-γ production were significantly inhibited in 
ETP-treated TCR-stimulated cells compared to DMSO control. Based on this observation, a 







Figure 6. Impact of Top2α inhibition on cytokine production in CD4+ T cells derived from 
healthy subjects. a) dose-dependent effect of Top2α inhibition on IL-2 and INF-γ production in 
CD4+ T cells treated with DMSO control or etoposide. Distinct observations from 4 samples 
recorded and data analyzed by using paired – tests. b) Representative flow cytometry dot plot 




The next step was to assess the proliferative potential of CD4+ T cells derived from HS under 
varying conditions (unstimulated, DMSO control, and ICRF193 treated ) after three days. Using 
CFSE dilution tracking dye, cell division, and proliferation was evaluated in T cells. As shown in 
Fig. 7, T cell proliferation was markedly inhibited in TCR-stimulated, ICRF-193-treated cells 
compared and to DSMO control, evidenced by the decreased number of proliferation cycles 
(denoted by the number of peaks). CFSE-labeled cells with no anti-CD3/CD28 stimulation were 
used as control. 
 
Figure 7. Impact of Top2α inhibition on T cell proliferation determined by flow cytometry 
Representative histogram of CFSE dilution comparisons in DMSO control (green histogram) and 
ICRF-193-treated (red histogram) TCR-stimulated cells after a 3-day culture in CD4+ T cells 
derived from healthy subjects. Distinct peaks represent cell generation cycles.  Overlaid 
histogram plot was generated by the FlowJo software.  
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Top2α Inhibition Induces T cell Apoptosis and Boosts Cleaved Caspase 3 Expression 
Since Top2α cuts and reseals double-stranded breaks (DSBs) in the DNA backbone, inhibition of 
its activity may lead to failure of rapidly resealing the backbone and as such, converts these 
transient breaks into permanent DSBs. We hypothesized that inhibition of Top2α expression and 
activity might drive these cells to DSB-mediated apoptosis. To this end, we measured apoptosis   
in TCR-stimulated cells exposed to varying concentrations of ICRF193 (0, 2, 4, and 8μg/ml) at 
different time points (day 0, 1, 2, 3, and 5) using Annexin V (Av) and 7-Aminoactinomycin D 
(7-AAD) staining as an indirect measure of membrane asymmetric changes that occur during 
apoptosis.  As shown in Fig. 8, ICRF-193-treated cells exhibited a time- and dose-dependent 
















Figure 8. Time- and dose-dependent increases in apoptosis in TCR-stimulated CD4+ T cells 
by flow cytometry. Representative dot plot image showing the time-dependent increase in Av 
and 7-AAD  staining in TCR-stimulated ICRF-193-treated cells compared to the DMSO control 
at different time points (0, 1, 2, 3, and 5 days).  Dot plots were generated by FlowJo software. 
 
To further validate the apoptosis data, cleaved caspase-3 expression was checked in ICFR-193-
treated cells by Western blotting.  As shown in Fig. 9, there was a significant upregulation of 







Figure 9. Effect of Top2α inhibition on Caspase-3 expression. Representative western blot 
image of cleaved caspase-3 expression in DMSO control versus ICRF-193 treated cells. β-actin 
was used as the loading control. Protein band intensity analyzed with ImageJ software. Summary 
data of cleaved caspase-3 expression generated by GraphPad Prism software are shown. Data 
analyzed by paired T-test, and n represents the number of subjects. 
 
Top2α Inhibition Induces Telomeric DNA Damage and Upregulates PARP1 Expression 
Since Top2α controls a plethora of gene activity by regulating the winding of the DNA double 
helix, we hypothesized that Top2α inhibition might induce a DNA damage response as a way to 
trigger T cell dysfunction. To this end, we measured γ- H2AX, a DNA damage response marker 
in ICRF-193-treated CD4+ T cells, and compared to DMSO control by flow cytometry. The 
samples were cultured for three days with anti-CD3/CD28 antibody stimulation. As shown in fig. 
10, ICRF-193-treated CD4+ T cells exhibited a significant increase in expression of  γ-H2AX 




Figure 10. Effect of Top2α inhibition on DNA damage response shown by flow cytometry 
Representative dot plot image showing significant activation of the DNA damage response 
marker, γ- H2AX in TCR-stimulated ICRF-193-treated CD4+ T cells compared to DMSO 
control after a 3-day culture. Dot plots generated by ImageJ software. Data were analyzed by 
paired T-test on the GraphPad prism software, and n represents the number of subjects.  
 
To ascertain that the topological DNA damage caused by Top2α inhibition extends to the 
telomeres, we visualized the dysfunctional telomere-induced foci (TIFs, a marker of telomeric 
DNA damage) by confocal microscopy following immunofluorescent staining. As shown in fig. 
11, the number of TIF per nucleus was significantly elevated in ICRF-193 and ETP-treated cells 
compared to DMSO control. Taken together, this data confirms our hypothesis that the 




Figure 11: Effect of Top2α inhibition on telomeric DNA by confocal microscopy 
Immunocytochemical staining of 53BP1(green) and TRF1(red). Dysfunctional telomere-induced 
foci per nucleus are identified by the foci that co-stained with TRF1 and 53BP1. The nuclei were 
stained with DAP1 (blue). Scale bar, 2 μm. Summary data of TIF per nucleus in TCR-stimulated 
CD4+ T cells exposed to ICRF-193, and ETP versus DMSO control. Data were analyzed by 
paired T-test on the GraphPad prism software, n represents the number of subjects tested.  
 
Top2α eliminates topological DNA constraints by creating topoisomerase 2 cleavage complexes 
(Top2cc), a crucial protein-DNA transient intermediate. Any alteration in Top2α activity can 
lead to the trapping of this Top2cc, causing DNA double-stranded breaks. Repair of Top2α 
induced DNA break is initiated by tyrosyl-DNA phosphodiesterase 2(TDP2) which catalysis the 
hydrolysis of the cleavage complexes; and requires the activation poly (ADP-ribose) polymerase 
(PARP). PARP acts as a DNA break sensor and parylates the target protein by catalyzing the 
transfer of ADP-ribose. To ascertain if Top2α-mediated DNA damage in T cells involves the 
cleavage of PARP1, we measured PARP1 expression in TCR-stimulated, Top2α-inhibited cells, 
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and DMSO control cells after three-day culture. As shown in fig. 12, significant upregulation of 
cleaved PARP1 was observed in the ICRF193-treated cells. 
 
Figure 12. Effect of Top2α inhibition on DNA damage repair protein. Representative 
western blot image and summary data of cleaved PARP1 expression are shown. β-actin was used 
as the loading control. Protein band intensity was analyzed with ImageJ software. Summary data 
of PARP1 expression was generated by GraphPad Prism software. Data were analyzed by paired 
T-test, n represents the number of subjects tested. 
 
Top2α Inhibition Induces Telomere Shortening by Disrupting the Integrity of the Shelterin 
Complex and Suppressing Telomerase Activity 
Chronic viral infections can cause telomere shortening. The outcome of telomere attrition is 
premature aging, T cell dysregulation, and immune senescence. To determine if Top2α inhibition 
leads to telomere attrition, we measured telomere length in TCR-stimulated, Top2α –inhibited 
cells and compared this to DMSO control after a five-day culture. As seen in fig. 13, there was a 
significant reduction in telomere length in Top2α-inhibited cells compared to DMSO control. 
This finding suggests that topological constraints can lead to telomere shortening, similar to what 




Figure 13: Effect of Top2α inhibition on telomere length measured by Flow-FISH 
Representative histogram image showing significant reduction telomere length in TCR-
stimulated, ICRF-193-treated CD4+ T cells compared to DMSO control after a 5-day culture. 
The histogram was generated by ImageJ software. Data were analyzed by paired T-test on the 
GraphPad prism software, n represents the number of subjects tested.  
 
The shelterin complex is a group of proteins that protects the ends of the linear chromosomes 
from DNA damage. It consists of six proteins, namely TRF1, TRF2, RAP1, TPP1, POT1, and 
TIN2. To this end, we explored the integrity of the shelterin complex in Top2α-inhibited cells, as 
shown in fig. 14, among the proteins examined, only TRF2 expression was significantly 
decreased. Even though TRF1 expression was decreased, it was not statistically significant. The 
expression levels of RAP1, POT1, and TPP1 were unchanged. These findings reiterate the results 
observed in primary CD4+ T cells derived from HCV-infected subjects. 33,35 
TRF2 is the essential protein that protects the chromosomal ends. It does this by preserving the 
appropriate structure at the telomere ends and prevents the end-to-end fusion of the telomere 
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termini and allows the recruitment of telomerase to the ends of the linear chromosomes. Its 
inhibition may lead to the inability of telomerase to access the telomeres. 
 
Figure 14: Effect Top2α inhibition on the integrity of the shelterin complex. Representative 
western blot image and summary data of the proteins in the shelterin complex. Statistically 
significant inhibition of TRF2 expression was observed. β-actin was used as the loading control. 
Protein band intensity was analyzed with ImageJ software. Summary data of expression profile 
were generated by GraphPad Prism software. Data analyzed by paired T-test n represents the 
number of subjects. 
 
The human T cells lose an average of 50 base pairs of telomeric DNA per cell division. The 
activity of telomerase replenishes the telomeres. The human telomerase comprises a catalytic 
portion-human telomerase reverse transcriptase (hTERT) and the telomerase RNA (TR), which 
is the RNA component. Evaluation of the telomerase activity is a commonly used molecular tool 
in understanding the possible mechanisms of T cell senescence. To this end, we examined the 
gene expression levels of telomerase by RT-PCR and telomerase activity by the telomeric repeat 
amplification protocol (TRAP) assay in CD4+ T cells exposed to ICRF-193 and compared it to 
DMSO control. As shown in fig. 15, while there was no significant difference in telomerase 
50 
 
expression levels in the Top2a-inhibited cells, there was a significant inhibition in telomerase 
activity, recapitulating what was observed in chronic HBV, HCV, and HIV infection.   
 
Figure 15. Effect of Top2α inhibition on telomerase activity. Relative hTERT expression 
measured by RT-qPCR and telomerase activity measured by TRAP assay in ICRF193 treated 
cells versus DMSO control. n represents the number of subjects. 
 
Top2α-mediated DNA Damage Suppresses the DNA Damage repair kinase Ataxia 
Telangiectasia-Mutated (ATM) 
In response to double-stranded DNA damage, well-coordinated signaling repair pathways are 
activated to repair the damage. The initial response includes the upregulation of the activity of 
the cell cycle checkpoint genes and the halting of the cell cycle advancement. This allows time 
for the repair of DNA in the damaged cell. Failure of the cells to repair their double-stranded 
breaks lead to the activation of the DDR pathways by the phosphatidylinositol -3 kinase-related 
kinases (PIKK). The major kinases in this group are the ataxia telangiectasia-Mutated (ATM), 
ataxia telangiectasia and Rad3 Related (ATR), and DNA-dependent protein kinase c (DNA-
PKcs); and they are crucial in maintaining genomic stability.  While unrepaired single-stranded 
breaks lead primarily to the activation of ATR, ATM and DNA-PKcs are predominantly 
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activated in response to double-stranded DNA breaks. To this end, we explored the involvement 
of ATM in Top2α-mediated DNA damage. The expression profile of ATM was examined in 
TCR-stimulated CD4+ cells exposed to DMSO (control) and (ICRF193 treatment) at different 
time points (6h, 24h, 48h, and 72h) by western blotting. As shown in fig. 16, there was an 
increased expression of ATM in the early stage (6-24h) in response to DNA damage, followed 
by a gradual decline in the later phase (48h-72h) in ICRF-193-treated cells. This finding 
recapitulates what was observed in chronically HCV infected individuals.33 
 
Figure 16. Expression kinetics of ATM in TCR-stimulated, Top2α-inhibited CD4+ cells 
Representative western blot image and summary data showing the time-point of ATM 
expression. CD4+ T cells exposed to ICRF193 or DMSO control were cultured at different time 
points (6h, 24h, 48h, and 72h). GAPDH was used as the loading control. Protein band intensity 
was analyzed with ImageJ software. Summary data of ATM expression are generated by 










The goal of this study was to investigate the fundamental mechanism of telomeric DNA 
damage and immune evasion during chronic viral infections. Top2α removes supercoils and 
catenations during DNA related activities. Inhibition in the catalytic activity of Top2α leads to 
failure in the religation of the DNA backbone, and these transient breaks become converted to a 
permanent DNA break, which can be sensed as DNA damage and elicit the DNA damage 
response signals.  
In this project, we hypothesized that viral infection might disrupt the topology of DNA as 
a means to evade the immune system and maintain persistence. We found that Top2α protein 
level was significantly suppressed in chronic HIV, HCV, and HBV subjects than healthy 
subjects. To determine the level at which this inhibition might have occurred, we examined the 
mRNA expression of Top 2α. We found that there was no change at the mRNA levels, 
suggesting that Top2α protein is inhibited primarily at the translation level. Also, the DNA 
damage induced by Top2α leads to apoptosis and T cell dysfunction, and mirrored what was 
observed in chronic HIV and HCV individuals. 32,33 
Top 2α expression level is notably upregulated in rapidly growing cells such as cancer 
cells, as these cells undergo fast gene replications, recombination, and thus tangling of the DNA 
backbone is prone to occur. Top 2α activity is essential to prevent mitotic failure and ensure 
adequate cell proliferation. In our study, we observed that chronic viral infection suppressed 
Top2α expression and activity, thereby making CD4+ T cells dysfunctional and senescent. This 
indicates that adequate Top2α activity promotes T cell survival and function.  
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Another possible reason for the suppression of Top2α activity observed in this project 
could be that these viruses disrupt the mitochondrial function leading to an increase in the levels 
of reactive oxygen species (ROS). An increase in ROS generation may alter ATP levels, thereby 
making ATP unavailable for cellular processes. It is, therefore, pertinent to examine the 
mitochondrial kinetics in these cells. 
Furthermore, we ascertained whether the DNA damage induced by Top2α inhibition was 
widespread within the DNA or it extended to the telomeres. Telomere shortening or dysfunction 
is a feature of premature T cell aging observed in chronic HIV or HCV infections. Our finding 
suggests that the DNA damage caused by Top2α inhibition indeed extends to the telomere as it 
disrupts the shelterin integrity, inhibits telomerase activity, and leads to an increase in the 
number of dysfunctional telomere induced foci (TIF), visualized by confocal microscopy. 
Of the shelterin proteins, only TRF2 protein was significantly inhibited following Top2α 
inhibition. This suggests that TRF2 could be the significant shelterin protein affected by Top2a 
deficiency to cause telomeric DNA damage. This recapitulates the findings observed in 
individuals with chronic HCV infection. 33,35 While TRF2 degradation observed in chronic HCV 
individuals was noted to be due to a p53-dependent ubiquitin process; this pathway remained to 
be explored in the setting of Top2α inhibition. Also, the impact of TRF2 degradation on the 
mitochondrial function could be studied.  
Surprisingly, while the level of the human telomerase reverse transcriptase (hTERT) 
remained unchanged, its activity was significantly suppressed following Top2α inhibition. Many 
reports have observed a significant correlation of hTERT expression with telomerase activity in 
some carcinomas; however, this was not in this case. Well, evidence accumulates on telomerase 
activity linked with only full-length mRNA transcripts, whereas other alternatively spliced 
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variants of hTERT mRNA could inhibit telomerase activity. Whether this is the case in our 
observation, remains to be explored. 
In the event of DNA damage, the DNA repair kinases notably ATM are mobilized to the 
site of damage and phosphorylates downstream cell cycle checkpoint kinases CHK2 and CHK1. 
This halts the progression of the cell cycle and allows time for the damage to be repaired. In this 
study, we observed an initial induction of ATM expression in the early stages (6-24h) following 
ICRF-193 treatment and a gradual decline in expression in the later stages (48-72h). This finding 
is similar to what was observed in chronic HIV infected individuals. 55 Taken together, this could 
mean that ATM and TRF2 inhibition could be the key players involved in telomere dysfunction 
and cellular senescence during chronic viral infections.  
The findings from this study provide evidence that HBV, HCV, and HIV viruses evade 
the immune response by disrupting the DNA topology of the T cell. Since we have proved that 
Top 2α expression and activity is suppressed, further studies aimed at exploring the possible 
pathways of Top2α degradation should be studied. Since the ubiquitin-proteasomal protein 
degradation pathway usually degrades most mutated or truncated proteins, it would not be out of 
place to confirm if a similar pathway mediates the degradation of Top2α. CD4+ T cells from 
healthy subjects exposed to ICRF193 or etoposide could be treated with ubiquitin or proteasome 
inhibitor to see if Top 2α levels can be boosted. Similarly, Top2α overexpression experiments 
could be done in CD4+ T cells from chronic HIV, HCV, and HBV subjects to establish if the 
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